Watchlist Price Alert

Kymera Therapeutics Inc. (KYMR)

NASDAQ: KYMR · Real-Time Price · USD

31.20

-0.97 (-3.02%)

At close: May 13, 2025, 3:59 PM

31.13

-0.24%

After-hours: May 13, 2025, 06:31 PM EDT

-3.02% (1D)

Bid	28.77
Market Cap	2.03B
Revenue (ttm)	47.07M
Net Income (ttm)	-223.86M
EPS (ttm)	-2.98
PE Ratio (ttm)	-10.47
Forward PE	-7.33
Analyst	Buy

Ask	32.6
Volume	331,085
Avg. Volume (20D)	750,840
Open	32.30
Previous Close	32.17
Day's Range	30.46 - 32.38
52-Week Range	19.45 - 53.27
Beta	2.19

About KYMR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KYMR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KYMR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Kymera Therapeutics has released their quartely earnings on May 9, 2025:

Revenue of $22.1M exceeds estimates by $11.37M, with 114.83% YoY growth.

EPS of -0.82 exceeds estimates by 0.09, with -18.84% YoY decline.

Why Price Moved

3 months ago

+7.61%

Kymera Therapeutics shares are trading higher. Ste... Unlock content with Pro Subscription

3 months ago

+7.79%

Kymera Therapeutics shares are trading higher after the company announced it's targeting 2025 milestones with its STAT6 and TYK2 oral degraded programs for immunology.

News

4 days ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Found...

4 days ago · zacks.com

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

4 days ago · zacks.com

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.

2 weeks ago · fool.com

Why Kymera Therapeutics Stock Crushed it This Week

According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile bi...

1 month ago · zacks.com

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...

2 months ago · zacks.com

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.

2 months ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Fou...

2 months ago · zacks.com

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.25 per share a year ago.